Prelude Therapeutics (PRLD) Shares Outstanding (2019 - 2026)

Prelude Therapeutics has reported Shares Outstanding (Entity) for 8 years, with the latest figure at $82.5 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 8.6% year-over-year to $82.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.5 million (up 8.6% YoY) and the FY2025 annual result came in at $77.0 million, up 1.52% from the prior year.
• Shares Outstanding (Entity) climbed to $82.5 million in Q1 2026 per PRLD's latest filing, from $77.0 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $82.5 million in Q1 2026 and troughed at $47.1 million in Q1 2022.
• A 5-year average of $65.4 million and a median of $75.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) soared 58.65% in 2024, then increased 0.31% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $47.4 million in 2022, then rose by 27.41% to $60.4 million in 2023, then grew by 25.6% to $75.8 million in 2024, then gained by 1.52% to $77.0 million in 2025, then rose by 7.23% to $82.5 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $82.5 million, $77.0 million, and $76.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.